Clinical efficacy of alprostadil combined with butylphthalide on patients with acute ischemic stroke and its effect on hs-CRP
10.7501/j.issn.1674-6376.2016.07.020
- VernacularTitle:丁苯酞联合前列地尔治疗缺血性脑卒中的临床疗效及对hs-CRP的影响
- Author:
juan Wen WU
1
;
yuan Yuan TANG
;
jun Xiao YIN
Author Information
1. 河南科技大学第一附属医院神经内科
- Keywords:
ischemic stroke;
alprostadil;
butylphthalide;
clinical efficacy;
high sensitive C-reactive protein
- From:Drug Evaluation Research
2017;40(7):975-978
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical efficacy of alprostadil combined with butylphthalide on patients with acute ischemic stroke and its effect on hs-CRP.Methods Eighty-five patients with acute ischemic stroke admitted into our hospital were divided randomly into observation group (n =42) and control group (n =43).Patients in control group were treated with alprostadil,and those in observation group were treated with alprostadil combined with butylphthalide.The neurologic impairment score (NIHSS),ADL score,hs-CRP,coagulation function,and clinical efficacy in the two groups were observed and compared.Results After 14 days of treatment,the NIHSS and ADL score in both groups were improved,and NIHSS in observation group were much lower than control group,ADL were much higher,and hs-CRP were markedly lower than that of control (P ＜ 0.05).And the coagulation function indexes in both groups were obvious lowered,and DD and FIB in observation group were conspicuously lower than those in control group,and PT were much higher (P ＜ 0.05).In addition,observation group with effective rate of 90.5％ were significantly higher than that of control group with 72.1％ (P ＜ 0.05).Conclusion Compared with only alprostadil treatment,alprostadil combined with butylphthalide had a better capability of treating patients with acute ischemic stroke by improving coagulation function and neurologic function,and inhibiting levels of hs-CRP.
